Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Iruthayaraj, Ancy"'
Publikováno v:
In Bioorganic Chemistry June 2024 147
Autor:
Abdulhaniff, Parveen, Sakayanathan, Penislusshiyan, Loganathan, Chitra, Iruthayaraj, Ancy, Thiyagarajan, Ramesh, Thayumanavan, Palvannan
Publikováno v:
In Computational Biology and Chemistry June 2024 110
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Iruthayaraj, Ancy, Chinnasamy, Kalaiarasi, Jha, Kunal Kumar, Munshi, Parthapratim, Pavan, Mysore S., Kumaradhas, Poomani
Publikováno v:
In Journal of Molecular Structure 15 March 2019 1180:683-697
Autor:
Iruthayaraj, Ancy1, Kumaradhas, Poomani1 kumaradhas@yahoo.com
Publikováno v:
American Journal of Biomedical Sciences. 2020, Vol. 12 Issue 3, p191-205. 15p.
Autor:
Ramakrishnan, Jaganathan, Kandasamy, Saravanan, Iruthayaraj, Ancy, Magudeeswaran, Sivanandam, Chinnasamy, Kalaiarasi, Poomani, Kumaradhas
Publikováno v:
Applied Biochemistry and Biotechnology
The unprecedented coronavirus SARS-CoV-2 outbreak at Wuhan, China, caused acute respiratory infection to humans. There is no precise vaccine/therapeutic agents available to combat the COVID-19 disease. Some repurposed drugs are saving the life of dis
Publikováno v:
Journal of Biomolecular Structure and Dynamics
Journal of Biomolecular Structure & Dynamics
article-version (VoR) Version of Record
Journal of Biomolecular Structure & Dynamics
article-version (VoR) Version of Record
Initially, the SARS-CoV-2 virus was emerged from Wuhan, China and rapidly spreading across the world and urges the scientific community to develop antiviral therapeutic agents. Among several strategies, drug repurposing will help to react immediately
Sifuvirtide (SFT) is the second generation inhibitor of HIV-1 gp41 fusion protein, which is under phase III clinical trial for anti-HIV. However, over a period of time virus develops resistance against SFT. To overcome resistance, methionine and thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96eec06fc08307eb77f33a6f1dc6aedf
Autor:
Loganathan Chitra, Poomani Kumaradhas, Iruthayaraj Ancy, Thayumanavan Palvannan, Sakayanathan Penislusshiyan
Publikováno v:
Life Sciences. 245:117367
Aims The present study determines the effect of administration of novel antioxidant astaxanthin-s-allyl cysteine biconjugate (AST-SAC) against streptozotocin-induced diabetes mellitus (DM) in rats. Main methods AST-SAC (1 mg/kg/day) was treated again